Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

The early clinical evidence suggested ulixacaltamide could provide meaningful improvement over current therapies for ET ...

Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.

In December 2025, Praxis announced the successful completion of its pre-NDA meeting with the FDA, including the receipt of written feedback and an in-person meeting. The Company has aligned with the ...

Average approval time reduced by 2.5-3.5 years. Breakthrough therapy designation usually increases valuation significantly. Takeover offers typically increase with breakthrough therapy designations.

A trailer released for the game that’s shown above previews some of the monkey and Adventure Time characters that’ll be in the free mobile game along with the customization options that let players ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...

Ellen Sigal, the founder of the patient advocacy group Friends of Cancer Research (FOCR), is a self-described accidental tourist in the world of drug discovery. After completing a PhD in Russian ...